artemisinin/naphthoquine — Competitive Intelligence Brief

artemisinin/naphthoquine (artemisinin/naphthoquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium falciparum heme metabolism and mitochondrial electron transport Infectious Disease Small molecule

Target snapshot

artemisinin/naphthoquine (artemisinin/naphthoquine) — Ifakara Health Institute. Artemisinin acts as an antimalarial by generating reactive oxygen species that damage parasite proteins and membranes, while naphthoquine inhibits parasite heme polymerization and electron transport.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
artemisinin/naphthoquine TARGET	artemisinin/naphthoquine	Ifakara Health Institute	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and mitochondrial electron transport
IPTp-DP	IPTp-DP	Kenya Medical Research Institute	marketed	Antimalarial combination therapy	Plasmodium falciparum (malaria parasite)
Chloroquine + Primaquine	Chloroquine + Primaquine	U.S. Army Medical Research and Development Command	marketed	Antimalarial combination	Plasmodium parasite heme metabolism and mitochondrial function
Artemether-lumefantrine combination plus albendazole	Artemether-lumefantrine combination plus albendazole	Navrongo Health Research Centre, Ghana	marketed	Antimalarial combination with anthelmintic	Plasmodium falciparum (multiple mechanisms); Ascaris, Hookworm, Trichuris (tubulin)
chlorproguanil-dapsone plus artesunate	chlorproguanil-dapsone plus artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Dihydrofolate reductase (chlorproguanil/dapsone); mitochondrial function (artesunate)
lumefantrine plus artemether	lumefantrine plus artemether	Centers for Disease Control and Prevention	marketed	Antimalarial combination therapy	Malaria parasite heme metabolism and hemozoin formation
Artemether, Lumefantrine Drug Combination	Artemether, Lumefantrine Drug Combination	University of Yaounde 1	marketed	Antimalarial combination	Plasmodium falciparum heme and mitochondrial function

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class